Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis

Sankaranarayanan, 1998, Anticancer Res, Head and neck cancer: A global perspective on epidemiology and prognosis, 4779

Parkin, 2001, Int J Cancer, Estimating the world cancer burden: Globocan 2000, 153

Scharovsky, 2009, Curr Oncol, Metronomic chemotherapy: Changing the paradigm that more is better, 7

Kerbel, 2004, Nat Rev Cancer, The anti-angiogenic basis of metronomic chemotherapy, 423

Raina V, Tyagi BB, Manoharan N. Consolidated Report of the Population based Cancer Registries 2001-2004. National Cancer Registry Programme, Indian Council of Medical Research Bangalore; 2006.

Yeole, 2007, Asian Pac J Cancer Prev, Trends in incidence of head and neck cancers in India, 607

Molina, 2008, Cancer, African American and poor patients have a dramatically worse prognosis for head and neck cancer: An examination of 20,915 patients, 2797

Seiwert, 2005, Br J Cancer, State-of-the-art management of locally advanced head and neck cancer, 1341

Haddad, 2008, N Engl J Med, Recent advances in head and neck cancer, 1143

Argiris, 2011, Ann Oncol, Empowering induction therapy for locally advanced head and neck cancer, 773

Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.

Pignon, 2009, Radiother Oncol, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients, 4

Specenier, 2009, Oral oncology, Current concepts for the management of head and neck cancer: Chemotherapy, 409

Vermorken, 2007, N Engl J Med, Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer, 1695

Jensen, 2007, Radiother Oncol, Tumor progression in waiting time for radiotherapy in head and neck cancer, 5

Hanahan, 2000, J Clin Invest, Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, 1045

Browder, 2000, Cancer Res, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, 1878

Klement, 2000, J Clin Invest, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, R15

Andre, 2011, Future Oncol, Metronomic scheduling of anticancer treatment: The next generation of multitarget therapy?, 385

Pasquier, 2010, Nat Rev Clin Oncol, Metronomic chemotherapy: New rationale for new directions, 455

Rentschler, 1987, J Clin Oncol, Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas: A prospective, randomized study, 278

Rao, 1994, Am J Surg, Perioperative chemotherapy in patients with oral cancer, 262

Schifeling, 1994, Med Pediatr Oncol, Methotrexate content in squamous cell carcinoma of the head and neck after low-dose methotrexate, 88

Masferrer, 2000, Cancer Res, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, 1306

Gately, 2003, Prog Exp Tumor Res, Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis, 179

Khan, 2011, Br J Cancer, Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer, 1822

Ko, 2008, Oncology reports, Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma, 425

Bock, 2007, Cancer Res, Celecoxib toxicity is cell cycle phase specific, 3801

Kwak, 2007, Ann N Y Acad Sci, The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma, 99

Lai, 2008, Head Neck, Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract, 67

Lang, 2006, Int J Immunopathol Pharmacol, COX-inhibitors relieve the immunosuppressive effect of tumor cells and improve functions of immune effectors, 409

Raju, 2005, Int J Radiat Oncol Biol Phys, Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib, 520

Terakado, 2004, Oral oncol, Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma, 383

Raab, 2011, J Clin Oncol, The East Carolina Breast Center phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer, (suppl; abstr e11505)

Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00855881?show_desc=Y#desc. [Last accessed on 2013 Jun 27].

Hashitani, 2003, Int J Oncol, Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines, 665

Forastiere, 1992, J Clin Oncol, Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study, 1245

Glasner, 2010, J Immunol, Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor, 2449

Braakhuis, 2003, Cancer Res, A genetic explanation of Slaughter′s concept of field cancerization: Evidence and clinical implications, 1727

van, 2000, Cancer Epidemiol Biomarkers Prev, Oral field cancerization: Carcinogen-induced independent events or micrometastatic deposits?, 249

Feng, 2006, Laryngoscope, Chemopreventive effect of celecoxib in oral precancers and cancers, 1842

Kerr, 2010, N Engl J Med, Can we treat cancer for a dollar a day.Guidelines for low-income countries?, 801

Smith, 2011, N Engl J Med, Bending the cost curve in cancer care, 2060

André, 2013, Lancet Oncol, Has the time come for metronomics in low-income and middle-income countries?, e239